Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: Is redifferentiation akin phenomenon a reality in neuroendocrine tumors?

Simple item page
dc.contributor.authorBasu, Sandip
dc.contributor.authorOstwal, V.
dc.date.accessioned2017-04-03T06:41:09Z
dc.date.available2017-04-03T06:41:09Z
dc.date.issued2016
dc.description.divisionRMCen
dc.format.extent3381 bytes
dc.format.mimetypetext/html
dc.identifier.sourceNuclear Medicine Communications, 2016. Vol. 37 (6): pp. 669-671en
dc.identifier.urihttp://hdl.handle.net/123456789/14309
dc.language.isoenen
dc.subjectsomatostatin receptoren
dc.subject68Ga-DOTATATE PET-CTen
dc.subjecteverolimus and capecitabine-temozolamideen
dc.subjectredifferentiation akin phenomenonen
dc.subjectneuroendocrine tumorsen
dc.titleObservation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: Is redifferentiation akin phenomenon a reality in neuroendocrine tumors?en
dc.typeArticleen

Click here to download

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
0984.htm
Size:
3.3 KB
Format:
Hypertext Markup Language
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.81 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

2016